Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by Braidwell LP

Braidwell LP grew its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 32.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 615,531 shares of the biopharmaceutical company's stock after purchasing an additional 149,083 shares during the period. Braidwell LP owned 0.88% of Xencor worth $14,145,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of XNCR. BVF Inc. IL boosted its position in Xencor by 169.3% during the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock worth $52,596,000 after acquiring an additional 1,438,760 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Xencor by 23.7% during the 4th quarter. BNP Paribas Financial Markets now owns 16,528 shares of the biopharmaceutical company's stock worth $380,000 after purchasing an additional 3,171 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Xencor by 72.4% during the 4th quarter. Ameriprise Financial Inc. now owns 292,576 shares of the biopharmaceutical company's stock worth $6,723,000 after purchasing an additional 122,870 shares during the period. Comerica Bank boosted its holdings in shares of Xencor by 12.1% during the fourth quarter. Comerica Bank now owns 20,527 shares of the biopharmaceutical company's stock worth $472,000 after purchasing an additional 2,219 shares during the last quarter. Finally, TCG Crossover Management LLC grew its position in shares of Xencor by 1.0% in the fourth quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company's stock valued at $56,350,000 after purchasing an additional 25,000 shares during the period.

Insider Buying and Selling at Xencor

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the transaction, the executive vice president now directly owns 49,169 shares of the company's stock, valued at $542,334.07. This represents a 8.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.76% of the stock is currently owned by corporate insiders.

Xencor Stock Down 5.2 %

NASDAQ:XNCR traded down $0.46 during mid-day trading on Friday, hitting $8.33. The company had a trading volume of 935,748 shares, compared to its average volume of 640,463. Xencor, Inc. has a 1 year low of $7.16 and a 1 year high of $27.24. The business has a fifty day simple moving average of $10.85 and a 200-day simple moving average of $17.75. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $592.70 million, a price-to-earnings ratio of -2.60 and a beta of 0.99.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The firm had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company's revenue for the quarter was up 104.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.11) earnings per share. Equities analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Xencor in a research note on Wednesday, April 30th. William Blair assumed coverage on shares of Xencor in a research report on Monday, April 21st. They set an "outperform" rating for the company. StockNews.com lowered shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Barclays dropped their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday. Finally, Wells Fargo & Company reduced their target price on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Xencor has an average rating of "Moderate Buy" and an average price target of $29.50.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.